Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

吉非替尼 表皮生长因子受体 肺癌 癌症研究 基因 表皮生长因子 生物 癌症 受体 肿瘤科 医学 遗传学
作者
Federico Cappuzzo,Fred R. Hirsch,Elisa Rossi,Stefania Bartolini,Giovanni Luca Ceresoli,Lynne Bemis,Jerry Haney,Samir E. Witta,Kathleen D. Danenberg,I. Domenichini,Vienna Ludovini,Elisabetta Magrini,Vanesa Gregorc,Claudio Doglioni,Angelo Sidoni,Maurizio Tonato,Wilbur A. Franklin,Lucio Crinò,Paul A. Bunn,Marileila Varella‐Garcia
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:97 (9): 643-655 被引量:1569
标识
DOI:10.1093/jnci/dji112
摘要

BACKGROUND: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC. METHODS: Tumors from 102 NSCLC patients treated daily with 250 mg of gefitinib were evaluated for EGFR status by fluorescence in situ hybridization (FISH), DNA sequencing, and immunohistochemistry and for Akt activation status (phospho-Akt [P-Akt]) by immunohistochemistry. Time to progression, overall survival, and 95% confidence intervals (CIs) were calculated and evaluated by the Kaplan-Meier method; groups were compared using the log-rank test. Risk factors associated with survival were evaluated using Cox proportional hazards regression modeling and multivariable analysis. All statistical tests were two-sided. RESULTS: Amplification or high polysomy of the EGFR gene (seen in 33 of 102 patients) and high protein expression (seen in 58 of 98 patients) were statistically significantly associated with better response (36% versus 3%, mean difference = 34%, 95% CI = 16.6 to 50.3; P<.001), disease control rate (67% versus 26%, mean difference = 40.6%, 95% CI = 21.5 to 59.7; P<.001), time to progression (9.0 versus 2.5 months, mean difference = 6.5 months, 95% CI = 2.8 to 10.3; P<.001), and survival (18.7 versus 7.0 months, mean difference = 11.7 months, 95% CI = 2.1 to 21.4; P = .03). EGFR mutations (seen in 15 of 89 patients) were also statistically significantly related to response and time to progression, but the association with survival was not statistically significant, and 40% of the patients with mutation had progressive disease. In multivariable analysis, only high EGFR gene copy number remained statistically significantly associated with better survival (hazard ratio = 0.44, 95% CI = 0.23 to 0.82). Independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P-Akt-, or EGFR+/P-Akt- patients. CONCLUSIONS: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被一般路过科研人采纳,获得10
刚刚
sunnymoon发布了新的文献求助10
1秒前
lwt完成签到,获得积分10
1秒前
Orange的应助被ZZC采纳,获得10
1秒前
1秒前
Clover04的应助被DRJ采纳,获得10
1秒前
科研通AI6.2的应助被等待geduo采纳,获得10
1秒前
鲸鱼发布了新的文献求助10
2秒前
香蕉觅云的应助被刘2305采纳,获得10
2秒前
今后的应助被小小科研人采纳,获得30
2秒前
2秒前
3秒前
ZZZ完成签到,获得积分10
3秒前
刘欣悦发布了新的文献求助10
3秒前
锦李发布了新的文献求助10
3秒前
失眠中蓝完成签到,获得积分10
3秒前
CipherSage的应助被啊啊采纳,获得80
3秒前
4秒前
SciGPT的应助被wzj采纳,获得10
4秒前
云淡风轻完成签到,获得积分10
4秒前
完美夏天发布了新的文献求助10
5秒前
跟我回江南完成签到,获得积分10
5秒前
111完成签到,获得积分10
5秒前
啊啊发布了新的文献求助10
5秒前
5秒前
ZZZ完成签到 ,获得积分10
6秒前
6秒前
乐乐的应助被hehehe采纳,获得10
7秒前
7秒前
Huang完成签到,获得积分10
8秒前
8秒前
香蕉觅云的应助被zmh采纳,获得10
8秒前
9秒前
ghshen的应助被希音采纳,获得10
9秒前
9秒前
10秒前
weiwei完成签到,获得积分10
10秒前
传奇3的应助被ty12390采纳,获得10
10秒前
传奇3的应助被微风采纳,获得10
11秒前
董子瑜发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023